Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
Efficacy and Safety of Concizumab prophylaxis in patients with
haemophilia A or B without inhibitors
To establish the effect and investigate safety of daily subcutaneous treatment with concizumab prophylaxis when given to adult and adolescent haemophilia patients without inhibitors.
Male aged ≥12 years Body weight >25 kg at screening Congenital severe haemophilia A (FVIII < 1%) or moderate/severe B (FIX ≤ 2%) Documented treatment with coagulation factor containing product in the last 24 weeks
Exclusion Criteria:
Treatment with emicizumab within 180 days before screening Participation in any clinical trial of an approved or non-approved investigational product within 5 half-lives or 30 days from screening Known or suspected hypersensitivity to monoclonal antibodies History of thromboembolic disease inhibitors ≥0.6 BU in the last 5 years